WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction
WARCEF - Warfarn vs. Aspirin in Reduced Cardiac Ejection Fraction. Includes Change in Eligibility Criteria (Eligibility Ejection Fraction Has Been Increased From less than 30 to less than 35%) To compare the efficacy and safety of Warfarin (INR 2.0-3.0) with aspirin (325 mg per day) for preventing all-cause mortality and disability in patients with cardiac EF less than 35%.
Enrollment Complete; Intervention Continues
January 01, 2002
W. Scott Burgin, MD
Cheryl Weber, RN, MS, CCRC